To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma
Subjects participate voluntarily and sign informed consent.
Age ≥ 18 and ≤ 75 years old, male or female.
Histological or clinical diagnosis of HCC.
Barcelona Clinic Liver Cancer stage C. BCLC stage B, not suitable for radical surgery and/or local treatment
Histologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, etc.
History of malignancy other than HCC within 5 years prior to the start of study treatment.
History of liver transplantation, or planned to receive liver transplantation.
Moderate or severe ascites with clinical symptoms that require drainage, uncontrolled or moderate or severe pleural and pericardical effusion.